Fanconi anemia complementation group A protein (FANCA)

The Fanconi anemia complementation group A protein (FANCA) is a critical component of the FA core complex, which is essential for the cellular response to DNA interstrand cross-links (ICLs). FANCA facilitates repair of DNA damage that obstructs replication forks—particularly ICLs—by forming part of a multi-protein E3 ubiquitin ligase complex that monoubiquitinates FANCD2 and FANCI, a key step in triggering DNA repair processes. Mutations in the FANCA gene are the most common cause of Fanconi anemia, a syndrome marked by bone marrow failure, congenital abnormalities, and a high risk of cancers (notably leukemia and squamous cell carcinomas). FANCA is required for proper maintenance of hematopoietic stem cells and genomic stability, and its dysfunction can lead to hypersensitivity to DNA cross-linking agents used in cancer chemotherapy. While essential to DNA repair, FANCA is not a typical therapeutic target (with direct pharmacological modulators), but its status can inform treatment choices and prognosis, especially in oncology and hematology contexts [1][3][4][5][7][8].

Other names

FA complementation group AFAAFACAFA1FA-HFANCH

No established drugs directly target FANCA; indirect mechanisms involve induction of DNA cross-links (agents that rely on FA pathway status for efficacy or resistance)